US Supreme Court ruling could shield Bayer from thousands of Roundup lawsuits

The U.S. Supreme Court ruled 7-2 on June 25 in a decision that could sharply reduce Bayer’s exposure to thousands of Roundup lawsuits, holding that federal pesticide labeling law can preempt state failure-to-warn claims over cancer warnings.

The case, Monsanto Co. v. Durnell, reversed a $1.25 million Missouri verdict won by John Durnell and handed Bayer its most significant legal victory in years. The ruling does not resolve the broader scientific fight over whether Roundup causes cancer. Instead, it answers a narrower legal question: whether plaintiffs can sue under state law for not adding a warning that federal regulators did not require.

What the court decided

Justice Brett Kavanaugh wrote the majority opinion. Justice Ketanji Brown Jackson dissented.

The court said the Federal Insecticide, Fungicide, and Rodenticide Act can block state warning claims when the Environmental Protection Agency has not required the warning plaintiffs want on the product label. In practical terms, that gives Bayer a strong preemption defense in cases built around the argument that Roundup should have carried a cancer warning.

That legal distinction matters because Roundup litigation has largely centered on failure-to-warn claims. Plaintiffs have said users should have been warned that glyphosate-based herbicides could cause non-Hodgkin lymphoma. Bayer has long disputed that claim and has argued that its labels complied with federal rules.

The Supreme Court did not rule on the underlying cancer question. It focused on the relationship between federal labeling law and state tort claims, and on whether the company could be held liable in state court for not going beyond what federal regulators required.

Why the ruling matters for Bayer

The decision could affect thousands of pending cases in U.S. courts. Bayer has spent years dealing with Roundup verdicts, settlements and litigation costs after acquiring Monsanto in 2018, inheriting the herbicide business and its legal exposure.

A broad dismissal of warning-based claims would be a major shift in that fight. Bayer said the ruling should help contain the litigation, lead to the dismissal of current warning-based claims and bar future failure-to-warn claims. The company also welcomed the decision as good for science, farmers and industries that need regulatory clarity for innovation.

That message aligns with the core business risk for Bayer: not whether it can win every individual case, but whether the legal system will continue to allow large numbers of state-law suits to proceed around a label warning that the EPA has not demanded.

The ruling also has financial implications beyond the courtroom. Fewer viable claims would reduce legal costs and could improve Bayer’s ability to manage the remaining litigation over time.

The case behind the ruling

The Supreme Court’s decision came out of a Missouri case in which John Durnell won a $1.25 million verdict before the high court stepped in. The reversal removes one of the lower-court outcomes plaintiffs had used to argue that Roundup warning claims can survive.

The Associated Press reported the ruling the day it was issued, and other outlets including The Guardian, MarketWatch and The Wall Street Journal confirmed the 7-2 split and the preemption rationale. Le Monde later reported that the decision could shield Bayer from thousands of lawsuits tied to Roundup and cancer warning claims.

The legal issue at the center of the case is not new. For years, Bayer and Monsanto have argued that federal pesticide labeling rules should control when the EPA has not required a cancer warning. Plaintiffs have argued the opposite: that companies still had a duty under state law to warn consumers directly.

The Supreme Court sided with Bayer on that preemption question.

Settlement pressure and next steps

The ruling lands against the background of Bayer’s broader settlement strategy. In February 2026, the company agreed to a proposed $7.25 billion settlement to resolve pending and future glyphosate-related claims, subject to approval.

That settlement effort was designed to help bring closure to one of the longest-running mass torts in the U.S. The Supreme Court’s decision could strengthen Bayer’s hand by cutting down the number of active warning claims and reducing the leverage of plaintiffs still pressing those cases.

What happens next will depend on how quickly lower courts apply the ruling. If judges begin dismissing pending warning-based cases, Bayer could see a faster decline in litigation exposure and legal spending.

Another open question is whether the settlement proposal advances more smoothly now that the company has a major Supreme Court win behind it. The ruling does not end every Roundup-related dispute, but it changes the legal terrain in Bayer’s favor.

Broader implications

The decision may matter beyond Roundup. Other pesticide liability cases that rely on state warning claims could face stronger preemption arguments if the federal government has not required the specific warning at issue.

That makes the EPA central to the next phase of the dispute. The agency has not required a cancer warning on glyphosate-based Roundup labels, and the court’s ruling gives that regulatory posture legal significance in future cases.

For now, the Supreme Court has not settled the scientific debate over Roundup and cancer. It has decided who gets to control the warning label, and that decision could eliminate a large share of the lawsuits Bayer has been facing.